Latest news with #TAMP
Associated Press
13 hours ago
- Business
- Associated Press
WealthTech Strategy Partners Adds Dedicated TAMP Advisory Initiative
New offering provides growth strategy, M&A advisory, and market intelligence to Turnkey Asset Management Platforms (TAMPs) and their investors BOSTON, MA, UNITED STATES, June 3, 2025 / / -- WealthTech Strategy Partners, the only investment bank solely focused on WealthTech, today announced the formal launch of its dedicated advisory initiative for Turnkey Asset Management Platforms (TAMPs). With decades of industry insight and a growing demand for specialized strategic support, this new offering aims to connect TAMP providers, investors, and acquirers with the guidance needed to navigate a rapidly evolving market. The initiative will center around three core service areas: 1. Advisory for TAMP Operators – Helping platforms define growth strategy, improve positioning, and plan for scale or exit. 2. Strategic M&A and Capital Raising – Finding the right fit and valuation for a strategic exit or growth capital. 3. TAMP Market Intelligence & Mapping – Offering research, comparative analysis, and deal insights across the TAMP ecosystem. To lead this effort, WealthTech Strategy Partners has brought on Scott MacKillop, a pioneer in the TAMP world with more than 45 years of experience building, advising, and leading firms in the space. Scott was the Founder and CEO of First Ascent Asset Management (acquired by GeoWealth in 2023) and previously served as President of Frontier Asset Management, US Fiduciary Services, and other leading platforms. 'Traditionally, TAMPs have been considered more of a service offering than a technology,' said Kendrick Wakeman, Co-Founder and CEO of WealthTech Strategy Partners. 'However, the more TAMPs evolve, the more emphasis is placed on how these services are accessed, consumed, executed, and maintained. This has led to TAMPs evolving into technology platforms, often in their own right.' WealthTech Strategy Partners invites TAMP executives, private equity firms, venture capital investors, and strategic acquirers to sign up for early access to TAMP research and be the first to receive the upcoming white paper by subscribing to the WealthTech Strategy Partners TAMP Newsletter. About the firm: WealthTech Strategy Partners is the only investment bank solely focused on WealthTech. The firm advises early- to mid-stage technology companies and financial sponsors on capital raises, mergers & acquisitions, and strategic growth initiatives. Its team brings decades of domain expertise, purpose-built to serve innovators across the advisor technology ecosystem. Learn more at Kendrick Wakeman WealthTech Strategy Partners [email protected] Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hype Malaysia
18 hours ago
- Entertainment
- Hype Malaysia
Interview: PSYCHIC FEVER From EXILE TRIBE On Their New Album, Solo Projects & Anniversary Plans
J-pop sensations PSYCHIC FEVER From EXILE TRIBE had an eventful 2024, from kicking off their first Asia Tour, which included a stop at Zepp Kuala Lumpur, to releasing back-to-back hits. While we've just ended the first half of 2025, the seven-membered group have already cleared several things off their wish list, including their first U.S tour. Fresh off the release of their latest single, 'Gelato', we spoke to the members to learn more about the new track and their new album, 'PSYCHIC FILE III', now out digitally on music streaming platform. We also got to hear their touring plans for 2025, what they have up their sleeves for their upcoming anniversary and what the members are working on solo projects – so keep on reading to learn more. 1. The last time Hype Malaysia spoke to PSYCHIC FEVER was after the release of your single, 'Talk To Me Nice'. What have you guys been up to since then? RYOGA: Since 'TALK TO ME NICE feat. TAMP,' we've been busy growing both on and off stage! We just wrapped up our first U.S. tour, which was an incredible experience that really pushed us to connect with fans worldwide. We also signed with Warner Music Group, which opened a lot of new doors for us. WEESA: On the creative side, we've been working hard on new music—like our latest single 'Gelato' and the upcoming EP, PSYCHIC FILE III. It's been a busy but exciting time, and we're looking forward to sharing more of our journey with everyone. 2. You've recently released a new song, 'Gelato', which is a pre-release track from your upcoming album. Can you share more about this new song? KOKORO: 'Gelato' is a song that really captures the feeling of a summer romance—light, refreshing, and a bit bittersweet. Musically, it blends alternative R&B with some electro-disco and synthwave elements to create a cool, breezy vibe. WEESA: Lyrically, it talks about the excitement and urgency of a love that can't wait, kind of like how gelato melts fast in the summer heat. It's a track that shows a new, softer side of PSYCHIC FEVER while still keeping that hip-hop energy we're known for. We're really proud of it and hope listeners feel that summer warmth when they hear it. 3. You've already performed 'Gelato' at the EXPO2025 LDH DAY SPECIAL 'Jr. EXILE LIVE' concert last April. What was the fans' reaction to the song and the performance? REN: After performing, I felt really good about it. Even though the audience wasn't familiar with the song, by the end of it, they were vibing along with the music, which made me really happy. JIMMY: It was our very first time performing both the track and the choreography, but I felt a positive reaction. We had a really short time to learn the choreography, and we all practiced for long hours, so I was a bit nervous. But during the performance, seeing everyone's excited expressions in the crowd made me genuinely happy! 4. Before 'Gelato', you released three singles in early 2025: 'Paradise', 'What's Happenin'' and 'Wonder Woman'. Can you share more about these songs? KOKORO: Compared to our past releases, 'Paradise' is the most luxurious and mature love song we've done so far. The chorus blends both English and Japanese lyrics, creating a unique expression that somehow lingers in your ears. We took on a lot of new challenges with this track, including the music video, so I'd be really happy if you checked it out! WEESA: All three tracks are completely different in genre, so I hope at least one of them resonates with your personal taste. 'What's Happenin'' was produced by JP THE WAVY, just like 'Just Like Dat', and it carries his signature style. 5. 'Gelato' is part of your upcoming EP, 'PSYCHIC FILE III'. Tell us more about this new album. JIMMY: We're really excited about 'PSYCHIC FILE III'! It's a mix of different sounds and stories that show where we're at right now. You'll hear some upbeat tracks like 'Gelato' that are perfect for summer vibes, but also some deeper, more personal songs. RYUSHIN: We wanted the EP to feel like a journey, showing different sides of PSYCHIC FEVER—from fun and playful to honest and emotional. We can't wait for everyone to hear it! 6. Do you guys have a favourite track from the new album? Which song is it and why? TSURUGI: My pick is 'Reflection'! This song focuses heavily on vocal delivery and rhythmic expression. The performance is super cool too, so I really hope you'll check it out! REN: 'Reflection' is my favorite. It's an R&B/Hip-Hop track inspired by the early 2000s. It has a strong sense of momentum and an easy-to-follow rhythm—one of those songs that just makes you want to dance as soon as you hear it. KOKORO: I'd say 'Gelato'. It's a sweet summer love song that melts like gelato, capturing a new kind of PSYCHIC FEVER charm. It's a track that feels like a cool breeze laced with passion on your skin, and I'd be really happy if you could enjoy that feeling too. RYOGA: My favorite is 'PROMISE'. This song was made for all our fans—ForEVER—who always support us. It carries the message: 'We want to always be with you and keep moving forward together,' which is why we named it PROMISE. It's filled with gratitude for the people we've met, and the hope of fulfilling dreams together with everyone we'll meet in the future too. I'd be really happy if this song becomes something special for you as well. JIMMY: For me, it's 'EVOLVE'. I did the hook for this one, and honestly, it was the toughest recording I've ever done. I changed microphones three or four times to find the right one for my voice, and I experimented a lot with vocal techniques—so this song really holds a special place in my heart. RYUSHIN: I also chose 'Reflection'. The track itself is really cool, and the choreography, just like 'Paradise', was created by ReiNA from RHT. She did an amazing job, so I hope people will pay close attention to that as well. WEESA: My pick is 'Reflection', too. I love the vibe of the song, and it's super fun to sing. I can't wait to perform it on stage! 7. You completed your first U.S. tour last February, but you're going back on tour later this year. What do you guys have planned for your Japan tour? TSURUGI: The title of the tour is 'EVOLVE', so we're ready to show you how we've grown and evolved! We'll be performing lots of new songs, as well as existing tracks we've never showcased live before—so please look forward to it! RYOGA: Our Japan tour kicks off this June, with five shows currently scheduled. The theme is EVOLVE—we hope to show you the many ways we've continued to grow and transform. We're also preparing to bring the tour overseas, not just in Japan. We hope to share some exciting news with you soon, so stay tuned! And most of all, we truly can't wait to see all of you again very soon. 8. You're also going on a fanmeet tour in Europe and the U.S. This is also the first time you're touring in Europe. How do you feel about this new achievement? RYUSHIN: I'm truly happy and filled with gratitude. We've had the chance to visit before, but this will be our very first solo event there, so we really hope that everyone who comes will leave wanting to see us again. We'll do our best to deliver something amazing, with everything we've got! JIMMY: I'm super excited about going to new places and being able to perform. There are ForEVERs we haven't met yet, and people who might not know about us at all—so I want to give it my all to show them what we're all about, right in front of their eyes. I'm also really curious to see how people will react! 9. Do you guys also have plans to perform in Asia later this year? How about returning to Malaysia? KOKORO: Since this is EVOLVE 'in JAPAN', we're aiming to take it even further to other countries as well. We'll continue working hard so that we can visit Malaysia too, and I'll do my best to meet all our Malaysian ForEVERs as soon as possible! RYOGA: Absolutely—we definitely want to visit Malaysia again. Whether it ends up being a concert or a fan meeting, we can't say just yet, but we are preparing something that will give us a chance to meet all of you. Please look forward to it! 10. PSYCHIC FEVER will celebrate its anniversary in July. Do you guys have any plans on how to celebrate? REN: I definitely want to do something special. We're planning to have a fan meeting in the UK on July 13, so we'll be able to celebrate not just as a group, but together with all of you. I hope we can create a memorable moment with everyone on that day. JIMMY: We'll be in London on that day, so I'd love to celebrate with not only our local ForEVERs but also fans from all around the world. Lately our schedules have been so packed that we haven't even had time to go out for a meal as a group, so I'd also love for the seven of us to go out and eat together! 11. What are the members' solo plans for 2025? Are you guys working on anything? REN: First, I want to keep improving my individual skills. Rather than being satisfied with where I am now, I plan to continue working hard so I can always show up as the best version of myself when I meet everyone. I also want to make full use of social media to showcase our unique strengths. For me, that means sharing my beatboxing and singing more so that even people who don't yet know us can discover what I bring to the group. I'm always mindful of that as I continue putting myself out there. KOKORO: I'm excited to announce the release of my first photobook, 'Kokoro no Oto'. It's packed with elements that really reflect who I am, so I'd be really happy if you checked it out! 12. Can you share a few words for your fans in Malaysia? TSURUGI: Thank you always for listening to our music! I really can't wait to see you all. I promise we'll come to see you, and when we do, let's spend an amazing time together! REN: I truly hope we can perform in Malaysia someday, and when that time comes, I'd love for you to come and see us! We're working hard every day so we can bring our music and entertainment to everyone in Malaysia. Please continue to follow PSYCHIC FEVER and support our journey! KOKORO: Thank you so much for your warm support, always. It feels like time has flown by since our memories from the ASIA TOUR HEAT. With the release of 'PSYCHIC FILE III', we'll keep pushing forward so we can meet you all again soon. Please continue to look forward to our activities! RYUSHIN: Thank you always for your support. We were lucky enough to visit Malaysia last year during our Asia tour, and I really hope we can come back soon and perform again. I'd be so happy if everyone in Malaysia could look forward to that day with us! RYOGA: To all our ForEVERs—thank you so much for your endless support. We're doing our best as a group so we can bring you exciting news in the near future. Let's meet again very soon. I love you all. JIMMY: I'm really looking forward to meeting you all soon! It's been a while since we've been able to visit Malaysia, so we'll be doing our best to make a live or event happen there. Please keep supporting us—it truly means the world! WEESA: We haven't been able to go to Malaysia recently, so I really hope we can visit again soon. Until then, I'd love for you to keep enjoying our music! What's your Reaction? +1 0 +1 0 +1 0 +1 0 +1 0 +1 0
Associated Press
27-05-2025
- Business
- Associated Press
WealthTech Strategy Partners Taps Industry Veteran Scott MacKillop to Provide Strategic Advice to TAMPs
BOSTON, MA, UNITED STATES, May 27, 2025 / / -- WealthTech Strategy Partners, the only investment bank solely focused on WealthTech advisory, has announced the addition of Scott MacKillop as a Senior Advisor to bolster its TAMP strategic advisory business. With over 45 years of experience in the financial services industry, MacKillop brings a wealth of strategic insight and leadership to support the firm's continued growth and client success. Throughout his distinguished career, MacKillop has led and advised numerous prominent asset management and fiduciary service firms. He was the Founder and CEO of First Ascent Asset Management, a pioneer in flat-fee investment management that he sold to GeoWealth in 2023. He has also been the President of Frontier Asset Management, US Fiduciary Services, Trivium Consulting, Portfolio Management Consultants (PMC), and ADAM Investment Services. 'Scott is perfectly positioned to help lead our efforts to build out the TAMP portion of our advisory business,' remarked Kendrick Wakeman, CEO and Co-Founder of WealthTech Strategy Partners. 'I am confident that his knowledge, leadership, experience, and vision as a six-time TAMP innovator is going to be a huge benefit for our clients and the wealth management industry as a whole.' In addition to his executive leadership, MacKillop serves on the Board of Directors for the Institute for the Fiduciary Standard, reflecting his long-standing advocacy for investor protection and best practices in advisory services. MacKillop began his career as a lawyer in Washington, D.C., practicing from 1976 to 1991. He holds a law degree from George Washington University Law School and an undergraduate degree from Stanford University. 'Over the last 30 years, I have had the pleasure and honor of helping to move the TAMP industry forward in whatever ways I could,' said MacKillop. 'With the industry changing at a record pace, I am delighted to be part of the WealthTech Strategy team helping to keep the industry moving forward in the future.' For more information about WealthTech Strategy Partners, visit: Kendrick Wakeman WealthTech Strategy Partners email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
14-05-2025
- Business
- Yahoo
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
MOUNTAIN VIEW, Calif., May 14, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on May 21, 2025. Mr. Bagai will share recent business developments, highlighting continuing momentum with the Company's RenovoCath commercialization, as well as progress in the ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating RenovoRx's novel drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG) for treatment in locally advanced pancreatic cancer (LAPC), which is currently under investigation, and has not yet been approved for commercial sale. Fireside Chat Details:Date: Wednesday, May 21, 2025Time: 12:40 p.m. ETSpeaker: Shaun Bagai, CEOModerator: Scott Henry, AGP Managing Director and Healthcare AnalystWebcast: To schedule a one-on-one investor meeting with Mr. Bagai, please contact your A.G.P. representative or KCSA Strategic Communications at RenovoRx@ About RenovoCath Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: About the TIGeR-PaC Clinical Trial TIGeR-PaC is an ongoing Phase III randomized multi-center trial evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of LAPC. RenovoRx's first investigational drug-device combination product candidate using the TAMP therapy platform is enabled with the Company's FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy (intra-arterial gemcitabine, known as IAG). About RenovoRx, Inc. RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to target therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating our novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon new drug application approval by the FDA. RenovoRx is also implementing commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, certain of these customers have already initiated repeat orders as RenovoRx works to expand the number medical institutions that have initiated the process for RenovoCath purchase orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity either on its own or in tandem with a medical device commercial partner. For more information, visit Follow RenovoRx on Facebook, LinkedIn, and X. Cautionary Note Regarding Forward-Looking Statements This press release, the fireside chat referenced herein, and statements of the Company's management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our pre-clinical and clinical trials and studies, including the overall timing and timing for additional interim data readouts and full patient enrollment for our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential of RenovoCath® or TAMP™ as standalone commercial products, our anticipated timing for and levels of revenue generation from RenovoCath sales, and our commercialization plans in general, (iii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iv) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, commercial plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as "may," "expects," "plans," "aims," "anticipates," "believes," "forecasts," "estimates," "intends," and "potential," or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our execution of our commercial strategy for RenovoCath or our TAMP technology may not lead to viable or repeating revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of TIGeR-PaC and any other preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that we file from time to time with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law. View source version on Contacts KCSA Strategic CommunicationsValter Pinto or Jack PerkinsT:212-896-1254RenovoRX@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Shafaq News
23-04-2025
- Politics
- Shafaq News
Istanbul rocked: 6.2 magnitude earthquake rocks Istanbul
Shafaq News/ On Wednesday, a 6.2-magnitude earthquake struck Turkiye's largest city, Istanbul, injuring over 150 people in panic-related incidents, officials said. The epicenter was located in the city's Silivri district, according to Turkiye's Disaster and Emergency Management Authority (AFAD), the quake occurred at 12:49 p.m. local time (09:49 GMT) at a depth of nearly seven kilometers. The tremor was felt strongly across Istanbul — home to more than 15 million people — and in surrounding provinces, prompting many to flee buildings in fear. 📍 Ankara • AFAD BaşkanlıkBugün saat 12.49'da Marmara Denizi, İstanbul Silivri açıklarında meydana gelen 6.2 büyüklüğündeki depremin hemen ardından saat 13.15 itibarıyla Türkiye Afet Müdahale Planı (TAMP) devreye alınmıştır.İçişleri Bakan Yardımcısı Sn.Münir Karaloğlu… — AFAD (@AFADBaskanlik) April 23, 2025 Two aftershocks, each measuring 4.9 in magnitude, were recorded in the Sea of Marmara off the coast of Buyukcekmece at 13:02 and 15:12 local time. Interior Minister Ali Yerlikaya said the quake lasted 13 seconds. The Istanbul Governor's Office confirmed that 151 people were injured, most while attempting to flee buildings, and are receiving treatment in hospitals. Marmara Denizi içinde bugün saat 12.49'da 6.2 büyüklüğünde bir deprem meydana geldi. Yerin yaklaşık 7 km derinliğindeki deprem toplam 13 saniye sürdü.Silivri açıklarına 24 km uzaklıkta olan deprem başta İstanbul olmak üzere civar illerde de hissedildi. Saat 15.12'ye kadar en… — Ali Yerlikaya (@AliYerlikaya) April 23, 2025 The governor's office urged residents to avoid damaged or potentially unsafe structures, limit vehicle use, and refrain from using mobile networks unless necessary. According to the state-run Anadolu Agency, President Recep Tayyip Erdogan noted that authorities were closely monitoring the situation and that he had been briefed by key ministers and officials from AFAD. 'Thankfully, there appears to be no troubling situation at the moment,' he added. Turkiye is among the most seismically active countries in the world, situated atop two major fault lines. 6.2 Earthquake in #Istanbul, Turkey All networks are currently down, people are scared to go back to their homes There were 6 stronger aftershocks. #earthquake — climatenews (@climatenews__) April 23, 2025 The most devastating in recent history occurred on February 6, 2023, when a 7.8-magnitude earthquake struck southern Turkiye and northern Syria, resulting in over 59,000 deaths and widespread destruction.
